16.76
Tandem Diabetes Care Inc stock is traded at $16.76, with a volume of 1.64M.
It is up +0.96% in the last 24 hours and up +30.73% over the past month.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
See More
Previous Close:
$16.60
Open:
$16.92
24h Volume:
1.64M
Relative Volume:
0.71
Market Cap:
$1.15B
Revenue:
$1.03B
Net Income/Loss:
$-94.55M
P/E Ratio:
-11.96
EPS:
-1.4012
Net Cash Flow:
$-3.64M
1W Performance:
-9.26%
1M Performance:
+30.73%
6M Performance:
-24.20%
1Y Performance:
-19.27%
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Name
Tandem Diabetes Care Inc
Sector
Industry
Phone
858-366-6900
Address
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
TNDM
Tandem Diabetes Care Inc
|
16.76 | 1.15B | 1.03B | -94.55M | -3.64M | -1.4012 |
|
ABT
Abbott Laboratories
|
88.67 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
307.94 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
80.38 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
|
BSX
Boston Scientific Corp
|
46.76 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
86.28 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-19-26 | Upgrade | Truist | Hold → Buy |
| Mar-17-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-23-26 | Upgrade | Lake Street | Hold → Buy |
| Feb-20-26 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-27-26 | Resumed | TD Cowen | Buy |
| Dec-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-21-25 | Resumed | Stifel | Hold |
| Sep-08-25 | Initiated | Oppenheimer | Outperform |
| Aug-12-25 | Upgrade | Citigroup | Sell → Neutral |
| Aug-07-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-09-25 | Downgrade | Citigroup | Neutral → Sell |
| Jun-16-25 | Initiated | Truist | Hold |
| Apr-10-25 | Initiated | Mizuho | Neutral |
| Mar-05-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Mar-03-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| Oct-04-24 | Initiated | Goldman | Neutral |
| Oct-02-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-22-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-08-24 | Initiated | Canaccord Genuity | Buy |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-29-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-25-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Mar-26-24 | Upgrade | Stifel | Hold → Buy |
| Aug-04-23 | Downgrade | Citigroup | Buy → Neutral |
| May-05-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-24-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-15-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Aug-09-22 | Downgrade | Wells Fargo | Overweight → Underweight |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Underweight |
| Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-20-20 | Initiated | Wells Fargo | Overweight |
| Jul-31-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-18-20 | Reiterated | Raymond James | Outperform |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Mar-23-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-06-20 | Initiated | Raymond James | Outperform |
| Feb-04-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-18-19 | Initiated | Guggenheim | Buy |
| Oct-04-19 | Upgrade | UBS | Neutral → Buy |
| May-17-19 | Reiterated | BofA/Merrill | Neutral |
| May-13-19 | Initiated | SVB Leerink | Outperform |
| Mar-08-19 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-19 | Reiterated | BofA/Merrill | Neutral |
| Feb-27-19 | Reiterated | Lake Street | Buy |
| Nov-21-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-26-18 | Reiterated | Dougherty & Company | Buy |
| Sep-26-18 | Reiterated | Piper Jaffray | Overweight |
View All
Tandem Diabetes Care Inc Stock (TNDM) Latest News
Tandem Diabetes Care Q1 earnings call highlights - MSN
Tandem insulin pumps cleared in EU for expanded indications - MSN
TNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin Up - Eastern Progress
Tandem Diabetes Care Inc (TNDM) Shares Surge 5.1% -- What GF Sco - GuruFocus
TANDEM DIABETES CARE INC (TNDM) Stock Chart - ChartMill
Why Insulet thinks its fully closed loop system will stand apart from rivals - MedTech Dive
BofA Securities Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $25 - Moomoo
TNDM: Momentum builds with pharmacy transition, Mobi Tubeless launch, and international expansion - TradingView
Tandem Diabetes Care Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
3 takeaways from ADA - MedTech Dive
Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy - BioSpace
How The Investment Story For Tandem Diabetes Care (TNDM) Is Evolving Without New Analyst Targets - Yahoo Finance
Wall Street analysts see a 56.2% upside in Tandem Diabetes Care (TNDM): Can the stock really move this high? - MSN
Technical Reactions to TNDM Trends in Macro Strategies - Stock Traders Daily
Tandem Diabetes (TNDM) Secures CE Mark for Expanded Use of Insul - GuruFocus
Tandem Diabetes’ Insulin Pumps Win EU Nods for T2D, T1D in Pregnancy - Medical Product Outsourcing
Wall Street Analysts See a 56.2% Upside in Tandem Diabetes Care (TNDM): Can the Stock Really Move This High? - Yahoo Finance
Tandem Diabetes receives CE mark for expanded insulin pump uses By Investing.com - Investing.com Nigeria
Tandem Diabetes receives CE mark for expanded insulin pump uses - Investing.com
[Form 4] TANDEM DIABETES CARE INC Insider Trading Activity - Stock Titan
Diabetes tech companies are racing toward ‘fully closed loop’ devices. But automation comes with trade-offs. - MedTech Dive
Reasons to Add Tandem Diabetes Stock to Your Portfolio Right Now - Yahoo Finance
Tandem: Upgrading To Hold On A High-Stakes Pivot Story - Seeking Alpha
Tandem Diabetes Valuation: Is 1.1x Sales a Buy? - Yahoo Finance
Wells Fargo Upgrade Highlights Tandem Diabetes Care Pharmacy And Pump Shift - Yahoo Finance
Tandem Diabetes Care Hits Day High with 11.16% Surge in Stock Price - Markets Mojo
Tandem Diabetes Care (TNDM) CEO receives 191,103 RSUs under 2023 incentive plan - Stock Titan
Tandem Diabetes Care (TNDM) EVP awarded 29,136 RSUs under 2023 incentive plan - Stock Titan
Tandem Diabetes (TNDM) CFO receives 62,657 restricted stock unit award - Stock Titan
29,136 RSUs granted to Tandem Diabetes Care (TNDM) chief operating officer - Stock Titan
Tandem Diabetes Care (TNDM) EVP receives 29,136 RSU equity award - Stock Titan
Tandem Diabetes Care (TNDM) CTO awarded 26,003 RSUs under 2023 incentive plan - Stock Titan
Tandem Diabetes Care (TNDM) awards 29,136 RSUs to EVP & Chief Legal Officer - Stock Titan
TNDM Stock: What to Know About Tandem's 2026 Reset - TradingView
Why Is Tandem Diabetes (TNDM) Stock Soaring Today - Yahoo Finance
Why is Tandem Diabetes Care stock surging today? By Investing.com - Investing.com Canada
TNDM Upgraded by Wells Fargo -- Price Target Raised to $27 - GuruFocus
Tandem Diabetes (TNDM) Receives Upgrade from Wells Fargo - GuruFocus
Wells Fargo Upgrades Tandem Diabetes Care to Overweight From Equalweight, Adjusts Price Target to $27 From $21 - marketscreener.com
Tandem Diabetes Care Hits Day High with 12.82% Surge in Stock Price - Markets Mojo
Wells Fargo upgrades Tandem Diabetes stock rating on pharmacy outlook By Investing.com - Investing.com Canada
TNDM stock down following Q1 earnings & revenue beat, gross margin up - MSN
What Does Tandem Diabetes Care's Upsized Convertible Note Offering Mean for Investors - Kavout
Citi Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $17 - Moomoo
TNDM Maintained by Citigroup -- Price Target Lowered to $17 - GuruFocus
Tandem Diabetes Care Inc (TNDM) Shares Surge 12.9% -- What GF Sc - GuruFocus
Q1 2025 Tandem Diabetes Care Inc Earnings Call Transcript - GuruFocus
Tandem Diabetes Care Inc Stock (TNDM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):